UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033122
Receipt number R000037754
Scientific Title Denosumab and Alendronate, Examination of the effective of Glucocorticoid-induced Osteoporosis
Date of disclosure of the study information 2018/06/23
Last modified on 2019/12/24 09:51:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Denosumab and Alendronate, Examination of the effective of Glucocorticoid-induced Osteoporosis

Acronym

Denosumab and Alendronate, Examination of the effective of Glucocorticoid-induced Osteoporosis

Scientific Title

Denosumab and Alendronate, Examination of the effective of Glucocorticoid-induced Osteoporosis

Scientific Title:Acronym

Denosumab and Alendronate, Examination of the effective of Glucocorticoid-induced Osteoporosis

Region

Japan


Condition

Condition

Steroid induced osteoporosis

Classification by specialty

Endocrinology and Metabolism Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In this study, we examine the noninferiority of denosumab as compared with alendronate, which is regarded as the first-line drug in guidelines for treatment and management of steroid osteoporosis.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary endopoint is the bone density change after 6 months and 1 year at administration.

Key secondary outcomes

Secondary endpoints are the change of bone metabolism markers during the observation period, morphological vertebral fractures and clinical fractures of the observation period, change of the lumbar TBS and adverse events.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

the denosumab subcutaneous injection 6 months once treatment group

Interventions/Control_2

the the Alendronate oral weekly treatment group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who satisfy all of the following criteria are included in this study.
1)Patients over 18 years old, male and female unquestioned
2)Guidelines for management and treatment of steroid osteoporosis: Patients with a score of 3 or more with the 2014 algorithm

Key exclusion criteria

Patients falling under any of the following are excluded from this research.
1)Patients who may be pregnant or pregnant, patients who desire pregnancy
2)Patients already taking steroids
3)Patients receiving donosumab or bisphosphonate
4)Patient with a disorder delaying esophageal passage such as esophageal stenosis or achalasia (esophageal relaxation disorder)
5)Patients who are raising their upper body for more than 30 minutes or who can not stand
6)Patients with a history of hypersensitivity to denosumab and alendronate or other bisphosphonates.
7)Patients with hypocalcemia
8)Patients judged inappropriate as subjects by the attending physician

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Yosuke
Middle name
Last name Okada

Organization

University of Occupational and Environmental Health, Japan, School of Medicine

Division name

The First Department of Internal Medicine

Zip code

8078555

Address

1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555 Japan

TEL

093-603-1611

Email

y-okada@med.uoeh-u.ac.jp


Public contact

Name of contact person

1st name Keiichi
Middle name
Last name Torimoto

Organization

University of Occupational and Environmental Health, Japan, School of Medicine

Division name

The First Department of Internal Medicine

Zip code

8078555

Address

1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555 Japan

TEL

093-603-1611

Homepage URL


Email

torimoto@med.uoeh-u.ac.jp


Sponsor or person

Institute

The First Department of Internal Medicine
University of Occupational and Environmental Health, Japan, School of Medicine

Institute

Department

Personal name



Funding Source

Organization

The First Department of Internal Medicine
University of Occupational and Environmental Health, Japan, School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

University of Occupational and Environmental Health, Japan, School of Medicine

Address

1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555 Japan

Tel

093-603-1611

Email

sunday@pub.uoeh-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 06 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2014 Year 07 Month 01 Day

Date of IRB

2014 Year 08 Month 01 Day

Anticipated trial start date

2014 Year 07 Month 01 Day

Last follow-up date

2023 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 06 Month 23 Day

Last modified on

2019 Year 12 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037754


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name